CSL’s Profit Soars 17%, Plasma Business Boom

Australia-based pharmaceuticals company CSL reports 17% increase in half-year net profit

Australia-based pharmaceuticals company CSL has reported a 17% increase in its half-year statutory net profit, showcasing a strong performance in its main blood-plasma business. CSL’s statutory net profit for the six months through December was US$1.90 billion, surpassing market expectations of US$1.84 billion.